# NewLimit

> Therapeutics developer pursuing epigenetic reprogramming of aged cells.

## Why it is interesting

NewLimit's $435M June 2026 Series C backs a high-risk approach to aging-related disease; the next differentiator is whether reported cell reprogramming findings translate into human safety and efficacy.

## Profile

- **Latest funding:** Series C — $435M (June 2, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $435M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** Founders Fund, Thrive Capital, Greenoaks, Quiet Capital

## Funding history

- Series C · $435M · June 2, 2026
  Source: https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/newlimit